HC Wainwright Reiterates Buy Rating for TG Therapeutics (NASDAQ:TGTX)

HC Wainwright reaffirmed their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a report issued on Wednesday,Benzinga reports. The firm currently has a $55.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ FY2025 earnings at $1.26 EPS.

Several other brokerages have also recently issued reports on TGTX. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Finally, The Goldman Sachs Group boosted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $30.18 on Wednesday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a one year low of $12.84 and a one year high of $36.84. The company has a 50-day simple moving average of $31.69 and a 200-day simple moving average of $25.63.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the prior year, the company earned $0.73 earnings per share. The firm’s revenue was down 49.4% on a year-over-year basis. As a group, equities research analysts forecast that TG Therapeutics will post 0.07 EPS for the current year.

Insider Buying and Selling

In related news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,358 shares of company stock valued at $781,497. Corporate insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TGTX. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares in the last quarter. Blue Trust Inc. raised its position in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of TG Therapeutics in the third quarter valued at about $53,000. Values First Advisors Inc. purchased a new position in shares of TG Therapeutics during the 3rd quarter worth approximately $58,000. Finally, GAMMA Investing LLC increased its stake in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 2,171 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.